Global medical technology business Smith & Nephew experienced hard times in Europe in the third quarter and expects these to continue.
Revenue in the three months to September 29th was up an underlying 1% but down an actual 7.8% at $952m from $1,032m the year before. Profit before tax eased to $188m from $193m the year before.
The Advance Wound Management (AWM) division outperformed the Advanced Surgical Devices (ASD) side of the business.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AWM's revenue fell to $254m from $258m a year earlier, but with exchange rate fluctuations stripped out rose 4%.
The AWM trading margin was 2.5 percentage points (250 basis points) lower than the prior year at 22.9%,largely due to the settlement with Wake Forest University. Trading profit in the quarter was $58m, down from $66m in the third quarter of 2011.
ASD's revenue tumbled to $698m from $774m the year before, but would have been flat but for currency headwinds, which accounted for three percentage points of the fall, and the spin-off of Bioventus, which accounted for seven percentage points of the decline.
The group had $379m net cash at the period end, against net cash of $150m at the end of June and net debt of $196m a year earlier.
"We do not see any change in the outlook for the group as a whole for 2012; however, we continue to see variation in performance at a product franchise level," said Olivier Bohuon, Chief Executive Officer of Smith & Nephew.
"We are seeing significant challenges in Europe, where we have about 30% of our revenues, and expect this to continue," he added.
Broker Nomura said revenues were 2% below consensus expectations, while trading margins were more or less in line.
"Growth in knees has slowed to -1% (well below market rate of +2%), a
particular concern given knees have supported weak performance in hips over the past 8 quarters. Hips endured another very challenging quarter, with a -4% contraction (market rate of +0%)," the broker noted.
JH
